Epigenetic Drugs and Clinical Trials
Section edited by Richard Momparler and Nick La Thangue
This section publishes research on the potential of epigenetic agents for the treatment of diseases. Manuscripts on both preclinical and early clinical studies are welcome. Preclinical studies should include the rationale for translation of the activity of epigenetic agents from the bench to the bedside. The clinical trials on epigenetic agents should include the background, rationale, clinical design and key endpoints.